Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause VHL disease, a rare and autosomaldominant genetic syndrome. Because VHL protein (pVHL) is the master regulator of hypoxia-inducible factor alpha (HIFa), the most prominent feature of VHL disease is the deregulation of HIFa proteins. However, the precise mechanism by which the loss of pVHL function contributes to tumorigenesis is not fully understood. Here, we show that pVHL destabilizes the F-box protein Skp2, a chief component of Skp, Cullin, F-box-containing complex that promotes DNA synthesis in the S phase. The b-domain of pVHL interacts with Skp2, stimulating proteasome-dependent Skp2 degradation, but the destabilization of Skp2 does not depend on the E3 ubiquitin ligase activity of pVHL. Notably, the generation of DNA damage induces Skp2 degradation, which is attenuated by the suppression of endogenous pVHL expression. One possible mechanism of pVHL-dependent Skp2 degradation entails the antagonizing of Akt-mediated Skp2 phosphorylation, which maintains Skp2 stability. Reintroduction of VHL into VHL-null renal cell carcinoma (RCC) cells decreased Skp2 levels and restored DNA damage-dependent Skp2 degradation. These results identify the tumor suppressor function of pVHL in delaying the S-phase progression to inhibit cell proliferation on DNA damage. Clinically, this report explains as to why Skp2 accumulates abnormally in RCC tissues.
Introduction
Renal cell carcinoma (RCC), the most common form of adult kidney cancer, constitutes approximately 3% of all adult malignancies (Lam et al., 2005) . Clear-cell RCC is the predominant type of RCC, and germline mutations in the von Hippel-Lindau (VHL) gene account for 75% of all cases of sporadic RCC (Cohen, 1999) .
Moreover, 20% of clear-cell RCC cases are associated with the silencing of VHL expression by CpG island hypermethylation of its promoter (Banks et al., 2006) . Biallelic inactivation of VHL results in VHL disease, which is characterized by the development of retinal and central nervous system hemangioblastomas, RCC, pheochromocytoma, pancreatic islet cell tumors, and renal, pancreatic and epididymal cysts (Maher et al., 1991; Kaelin, 2002; Lonser et al., 2003; Maher, 2004; Nyhan et al., 2008) .
Notably, RCC is highly resistant to conventional radiation and chemotherapies, which is caused by functional defects in tumor suppressor programs after apoptotic stimuli (Lowe, 1995; Kawasaki et al., 1999) . In a previous study, we suggested that VHL is indispensable for proper transactivation of the tumor suppressor p53 in response to apoptotic stimuli in RCC (Roe et al., 2006) .
The VHL gene encodes two isoforms of the VHL protein (pVHL), the best characterized of which is the E3 ubiquitin ligase, which targets oxygen-dependent degradation of the a-subunits of hypoxia-inducible factor (HIF) (Maxwell et al., 1999) . HIF is a heterodimeric transcription factor that comprises b-and a-subunits (Wang et al., 1995) . In contrast to the constitutively expressed b-subunit, the regulatory a-subunit undergoes proteasomal degradation under normoxic conditions that have been triggered by oxygen-dependent prolyl hydroxylation, which allows pVHL to bind and polyubiquitination to occur (Maxwell et al., 1999; Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001; Jaakkola et al., 2001) .
Under hypoxic conditions, the absence of oxygendependent prolyl hydroxylation induces the accumulation of HIFa, its heterodimerization with HIFb and translocation to the nucleus to activate transcription of hypoxia-inducible genes that regulate angiogenesis, glucose metabolism, cell growth and cell cycle regulation (Semenza, 1999; Wykoff et al., 2004) .
Although the accumulation of HIFa contributes to renal cell carcinogenesis, other proteins that have no relationship to hypoxic induction are elevated in RCC, including X-linked inhibitor of apoptosis proteins, Mina53, Tmem22/Rab37 and Csk-binding protein (Langner et al., 2004; Ishizaki et al., 2007; Mizutani et al., 2007; Liu et al., 2008; Feng et al., 2009 ). Of such proteins, we studied the exaggerated expression of Skp2 in RCC, because ectopic expression of pVHL in 786-O RCC cells upregulates p27/kip1, which is targeted for degradation by Skp2 (Kim et al., 1998 (Kim et al., , 2004 .
Notably, decreased p27/kip1 and increased Skp2 correlate with tumor size, stage and grade, and metastasis (Osipov et al., 2002; Langner et al., 2004; Liu et al., 2008) . Moreover, recent studies have found many proteins, in addition to HIFa, to be negatively regulated by pVHL, such as atypical protein kinase C, myogenin and multiple subunits of RNA polymerase II, implying that pVHL has diverse tumor suppressor functions (Frew and Krek, 2008 ).
Yet, the precise molecular basis of the association of VHL mutations and Skp2 overexpression is unknown. Skp2 is part of the Skp, Cullin, F-box-containing E3 ubiquitin ligase complex, as are Skp1, Culin1 and Rbx1/ Roc1 (Nakayama and Nakayama, 2005) . Skp2 is overexpressed in various human cancers, including breast carcinoma, gastric carcinoma and prostate cancer, implicating Skp2 as an oncogene.
Generally, tumor suppressor cell cycle regulatory proteins are targeted by Skp2 for ubiquitination and proteolysis (Frescas and Pagano, 2008) . p27/kip1 is a crucial substrate for Skp2, based on the evidence that Skp2 and p27/kip1 double knockout mice overcome the phenotypes that result from Skp2 deficiency (Nakayama et al., 2004) . p27/kip1 is a cyclin-dependent kinase inhibitor that regulates entry into the G1 phase of the cell cycle; thus, low levels of p27/kip1 due to Skp2 accumulation contributes to uncontrolled tumor cell proliferation (Sherr and Roberts, 1995) .
In this study, we dissected the molecular mechanisms of deregulated Skp2 expression in RCC. We report that pVHL induces stabilization of p27/kip1, through reduced polyubiquitination and forced inhibition of endogenous VHL, which slows p27/kip1 induction on DNA damage. Regulation of p27/kip1 by pVHL prompted us to test whether pVHL affects Skp2 expression levels. We observed significant pVHLmediated downregulation of Skp2, especially when DNA damage-dependent Skp2 destabilization occurred. In contrast to p27/kip1, pVHL accelerated Skp2 polyubiquitination, but did not depend on the E3 ubiquitin ligase activity of pVHL. Consistent with these data, endogenous Skp2 expression levels differed between RCC cells that did or did not express pVHL.
Finally, an analysis of the contents of DNA synthesis in RCC cells showed that pVHL-deficient cells experienced abnormal synthesis of DNA during DNA damage. These results provide strong evidence of the antitumorigenic potential of VHL with regard to the regulation of the Skp2-p27/kip1 axis.
Results
Decreased polyubiquitination by pVHL is associated with p27/kip1 induction by apoptotic stimuli Adenovirus-mediated pVHL overexpression in a VHLdeficient kidney cancer cell line 786-O leads to cytotoxicity, contributed by increased p27/kip1 expression (Kim et al., 2004) . It was unknown, however, whether pVHL had general effects on p27/kip1 induction.
To determine whether forced expression of pVHL influenced p27/kip1 levels in other cell lines, we transiently transfected HA-pVHL into colon cancer HCT116 cells ( Figure 1a) . As expected, endogenous p27/kip1 levels were higher in ectopically overexpressed HA-pVHL-harboring HCT116 cells.
The activity of p27/kip1 is regulated by ubiquitinmediated degradation rather than transcription or translation (Hershko, 2008) . To investigate the function of pVHL in p27/kip1 stabilization, we performed an in vivo ubiquitination assay by transiently transfecting HEK293T cells with combinations of mammalian expression vectors that contained p27kip1, Flag-Skp2, HA-ubiquitin and HA-pVHL (Figure 1b) . For 16 h, cells were treated with 10 mM of the proteasome inhibitor MG132 at 24 h post-transfection. Then, cell lysates were co-immunoprecipitated with anti-p27/kip1 and immunoblotted with anti-ubiquitin, and vice versa, to detect changes in the ubiquitinated forms of p27/kip1. Consistent with our result of accumulation of endogenous p27/kip1 by ectopic HA-pVHL expression, the polyubiquitinated forms of p27/kip1 decreased dosedependently on HA-pVHL expression, suggesting that pVHL stabilizes p27/kip1 by blocking Skp2-mediated ubiquitination and subsequent degradation.
Recently, several reports have shown that apoptotic stimuli upregulated p27/kip1, which is required for cell cycle arrest and inhibition of cell growth, but the mechanism by which this event occurred was unidentified (He et al., 2006) . Unlike other tumor suppressors in which the loss of tumor suppressor function is caused by mutation or deletion, such as p53 and retinoblastoma, the p27/kip1 gene is rarely affected in human cancer (Pagano et al., 1995) . Therefore, we hypothesized that pVHL regulates the post-translational induction of p27/ kip1 in response to apoptotic stimuli.
Before testing this hypothesis, we examined the inhibition of endogenous pVHL in HCT116 cells by lentivirus-mediated short hairpin RNA (shRNA) (Figure 1c) . By reverse transcription-PCR (RT-PCR), pVHL mRNA levels declined in HCT116 cells. After establishing stable clones that constitutively expressed pVHL shRNA, we administered the genotoxic reagent adriamycin for 16 h and determined whether the status of pVHL affected the increased expression of p27/kip1 on DNA damage (Figure 1d) .
Similar to what has been reported, apoptotic stimuli induced p27/kip1 expression and pVHL knockdown cells experienced slower increases in p27/kip1, as expected. These results indicate that pVHL is crucial for upregulating p27/kip1 on DNA damage by inhibiting Skp2-mediated degradation.
pVHL associates with Skp2
Our results raised the possibility that positive regulation of p27/kip1 by pVHL resulted from decreased activity of the F-box protein Skp2. To test this hypothesis, we investigated whether pVHL interacted with Skp2 ( Figure 2a) . In HEK293T cells that transiently overexpressed Flag-Skp2 and/or HA-pVHL, HA-pVHL was detected with anti-Flag antibody co-immunoprecipitates. We also confirmed this binding by observing an interaction between recombinant glutathione S-transferase (GST)-fused pVHL and endogenously expressed Skp2 (Figure 2b ). To deem the bacterially purified recombinant GST-pVHL appropriate for our experiments, GST-pVHL was incubated with lysates from cells that overexpressed HA-HIF1a (Ohh et al., 2000) , which interacts with pVHL-we detected the interaction between HIF1a and pVHL ( Figure 2b , left panel). In similar GST pull-down experiments, endogenously expressed Skp2 as well as HA-Skp2 was detected in precipitates that were pulled down with GST-pVHL ( Figure 2b, right panel) .
To verify the endogenous interaction between pVHL and Skp2, endogenous Skp2, prepared from HCT116 lysates, was co-immunoprecipitated with anti-pVHL ( Figure 2c) . Consistent with the above data, antipVHL-incubated immunoprecipitates contained endogenous Skp2.
Next, we generated truncated forms of GST-fused recombinant pVHL-the a-domain (amino acids 155-213) and b-domain (amino acids 1-154)-and incubated them and full-length GST-pVHL with lysates from HA-Skp2-overexpressing cells (Figure 2d ). Like HIF1a, which associates specifically with the b-domain, HASkp2 bound to the b-domain of pVHL.
In addition to HIF1a, the b-domain of pVHL has been shown to be required to bind to 13 proteins (Leonardi et al., 2009) , suggesting that the tumor suppressor function of pVHL needs the b-domain to associate with other proteins. Our results raise the possibility that p27/kip1 induction, as shown by pVHL expression (Figure 1) , regulates Skp2 activity. pVHL increases Skp2 polyubiquitination, but does not require the E3 ubiquitin ligase function of pVHL Many studies have described the functions of Skp2 in cell cycle regulation, especially during G 2 -M progression, which directly targets cyclin-dependent kinase inhibitors. Notably, in the G1 phase, Skp2 is also regulated by targeted for proteolysis by another ubiquitin ligase anaphase-promoting complex/cyclosome and its activator, Cdh1 (Bashir et al., 2004) . Thus, we explored the possibility that Skp2 stability is regulated by pVHL by determining whether pVHL expression affected Skp2 levels ( Figure 3a) . Ectopic expression of HA-pVHL in HCT116 cells decreased the levels of endogenous Skp2 in a dose-dependent manner (Figure 3a , left). To exclude the possibility that decreases in Skp2 levels by pVHL resulted from the inhibition of transcription, we generated cDNA from HCT116 cells in the experiment mentioned above and performed RT-PCR using Skp2 mRNA-specific primers. There was no difference in Skp2 mRNA levels Next, we determined whether changes in Skp2 polyubiquitination by pVHL correlated with reductions in Skp2 levels. To this end, we performed an in vivo ubiquitination assay of ectopically expressed Flag-Skp2 with transiently transfected HA-ubiquitin and HApVHL in HEK293T cells (Figure 3c ). Notably, pVHL enhanced the ubiquitination of ectopic Skp2 significantly. We also confirmed increased ubiquitination of endogenous Skp2 by HA-pVHL expression (Supplementary Figure 1 ). Given the well-documented E3 ubiquitin ligase activity of pVHL, we should consider whether its activity regulates Skp2 destabilization.
To verify the effect of pVHL on Skp2, we used a patient-derived point mutant of pVHL. The arginine-toglutamine (R167Q) missense mutation, in the a-helical domain of pVHL, is predicted to disrupt elongin C recruitment, resulting in the loss of E3 ubiquitin ligase activity (Stebbins et al., 1999) . We found that the pVHL R167Q mutant still decreased endogenous Skp2 levels ( Figure 3d ). Moreover, both pVHL wild-type and R167Q mutant showed similar binding ability to Skp2 (Figure 3e ), supporting evidence that the regulation of 
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Skp2 stability is unrelated to the catalytic activity of pVHL. Next, we determined whether pVHL influences steadystate Skp2 levels in HCT116 cells. To investigate whether pVHL affected Skp2 stability, we administered cycloheximide for various times to HCT116 cells that stably expressed scrambled or pVHL shRNA to block protein neosynthesis and measured the half-life of Skp2 ( Figure 3f ). As expected, Skp2 degradation declined in VHL-silenced HCT116 cells. In control HCT116 cells, Skp2 protein levels decreased 50% during 1 h after cycloheximide addition, but Skp2 protein levels were relatively constant in pVHL-suppressed HCT116 cells and remained nearly 80% of basal level at 1 h (Figure 3g ). Collectively, these experiments strongly suggest that pVHL is a negative regulator of Skp2 stability. (g) Densitometry analysis was performed using National Institutes of Health ImageJ software to quantify the expression of Skp2. Skp2 band intensity was normalized to b-actin, then normalized to the t ¼ 0 controls.
Skp2 destabilization on DNA damage J-S Roe et al pVHL participates in rapid apoptotic stimuli-driven degradation of Skp2 Data shown above raised the possibility that functional inactivation of Skp2 might affect p27/kip1 induction; thus, we suspected that Skp2 is sensitized to DNA damage. To test this hypothesis, HCT116 cells were treated with adriamycin for various times and analyzed for changes in Skp2 levels (Figure 4a ). Consistent with previous results, p27/kip1 accumulated proportionally to treatment times. Notably, Skp2 protein, but not mRNA, degraded quickly relative to increases in p27/ kip1. Moreover, with increasing time and concentration of adriamycin treatment also failed to lead to change in the level of Skp2 mRNA, evaluated by qRT-PCR analysis (Figure 4b ). Furthermore, VHL inhibition effected decelerated Skp2 destabilization on DNA damage (Figure 4c ). Simultaneously, low rate of p27/ kip1 induction was also detected upon VHL inhibition, supporting that destabilization of Skp2 by pVHL was directly proportional to p27/kip1 induction (Figures 4c  and d ). This reduction and induction in DNA damageinduced Skp2 and p27/kip1 expression prompted us to investigate whether apoptotic stimuli could reinforce the binding of pVHL to Skp2. To determine the DNA damage-mediated enhancement in pVHL-Skp2 interaction, Flag-Skp2 and HA-pVHL were overexpressed in HEK293T cells for 24 h, after which we treated the cells with adriamycin for 4 and 8 h and analyzed the interaction by co-immunoprecipitation with anti-HA (Figure 4e ). The interaction between pVHL and Skp2 was significantly stronger in response to apoptotic stimuli.
On the basis of these results, we expected that destabilization of Skp2 on apoptotic stimuli depended on ubiquitination and proteasomal degradation and that pVHL controlled this regulation. Thus, we examined whether polyubiquitination of Skp2 was influenced by pVHL in response to apoptotic stimuli (Figure 4f,  Supplementary Figure 2) . By in vivo ubiquitination assay of endogenous Skp2 in HCT116 cells, we observed significant increases in the polyubiquitinated forms of Skp2, especially after adriamycin-induced DNA damage. Notably, inhibition of pVHL expression resulted in reduced Skp2 polyubiquitination on DNA damage, consistent with the above data. These results establish that pVHL increases the levels of polyubiquitinated Skp2, regardless of its E3 ubiquitin ligase activity, as shown in Figures 3d and e. Dependence of Skp2 regulation on pVHL by inhibition of Akt1-mediated phosphorylation Recently, Gao et al. (2009) suggested that Akt1 interacts with and phosphorylates Skp2 at Ser72, which is required for its exit from Cdh1-mediated degradation. On the basis of this report, we hypothesized that the interaction between pVHL and Skp2 blocks the access to Akt1 and negatively affects Skp2 stability.
To investigate whether pVHL affected Akt1-mediated Skp2 phosphorylation, we examined the competition of pVHL and Akt1 for Skp2 binding. HEK293T cells were co-transfected with Myc-Akt1, Flag-Skp2 and increasing amounts of HA-pVHL (Figure 5a ). When lysates were co-immunoprecipitated with anti-Flag to detect bound Akt1, pVHL expression blocked the Skp2-Akt1 interaction.
Because pVHL competes for the interaction between Skp2 and Akt1, we examined whether pVHL inhibited Skp2 phosphorylation at Ser72. To detect the phosphorylation status of Skp2, we performed anti-Flag coimmunoprecipitation of total cell lysates that overexpressed Flag-Skp2 and Akt1 and immunoblotting with anti-pan Akt substrate (Figure 5b ). Consistent with previous data, levels of Skp2 phosphorylation by Akt1 decreased owing to pVHL expression.
Because phosphorylated Skp2 acquired stability and then regulated cell cycle progression (Gao et al., 2009; Lin et al., 2009) , we proposed that pVHL preferred to interact with the dephosphorylated forms of Skp2. We generated site-directed S72D point mutant of HA-Skp2, which mimics phosphorylated Skp2, and compared binding affinities for Flag-pVHL ( Figure 5c ). As expected, the binding affinity of the S72D mutant HA-Skp2 for Flag-pVHL was diminished compared with wild-type HA-Skp2, and S72A mutant HA-Skp2 showed slightly increasing amount of Flag-pVHL binding compared with wild-type HA-Skp2.
Moreover, we observed greater destabilization of S72A HA-Skp2 by HA-pVHL compared with wild-type forms of HA-Skp2. However, phospho-mimetic S72D mutant was resistant to pVHL-mediated destabilization (Figure 5d ), which coincided with the result in Figure 5c . These data prompted us to test whether the loss of Skp2 phosphorylation at Ser72 was a prerequisite for destabilization in response to apoptotic stimuli.
To test the possibility that damage-dependent decreases in Skp2 levels interfere with changes in phosphorylation levels, we measured the phosphorylation of ectopically overexpressed HA-Skp2 (Figure 5e ). On treatment with DNA damage reagents, such as adriamycin and etoposide, Skp2 phosphorylation decreased. Collectively, these results suggest that the mechanism of pVHL-mediated Skp2 destabilization is attributed to the inhibition of phosphorylation by Akt1.
Deregulated S-phase progression in RCC4 cells is recovered by the reintroduction of pVHL
We examined whether the status of pVHL in RCC cells influenced their endogenous expression of Skp2 and sensitivity to apoptotic stimuli by establishing RCC4-derived cell lines that stably expressed wild-type HApVHL (RCC4/pVHL) or empty vector (RCC4). When these cells were treated with adriamycin, endogenous p53 was induced to a greater extent in RCC4/pVHL cells than in RCC4 cells, under normal conditions and after DNA damage (Figure 6a ), consistent with a previous report (Roe et al., 2006) .
In contrast, RCC4/pVHL cells expressed lower baseline levels of endogenous Skp2, which fell rapidly in response to apoptotic stimuli compared with RCC4 cells Skp2 destabilization on DNA damage J-S Roe et al (Figures 6a and b) . As observed previously, endogenously phosphorylated Skp2 decreased upon apoptotic stimuli in both RCC4 and RCC4/pVHL cells. Interestingly, RCC4/pVHL cells showed greater extent in decreasing amount of Skp2 phosphorylation upon DNA damage. These results suggest that the restoration of pVHL in RCC4 cells is sufficient to recover the ability to arrest the cell cycle on DNA damage. The degradation of p27/kip1 by Skp2 promotes the activity of cyclin-dependent kinases and drives cells into the S phase (Montagnoli et al., 1999) . To determine whether proper Skp2-dependent entry into the S phase was affected by pVHL, we counted the S-phase population in RCC4 cells by bromodeoxyuridine (BrdU) labeling (Figure 6c) . By confocal microscopy of the BrdU-positive population, the S-phase contents of RCC4 cell lines were distinct-more RCC4 cells were BrdU positive under normal conditions compared with RCC4/pVHL cells, which experienced uncontrolled DNA synthesis, frequently observed in cancer cells. Notably, RCC4/pVHL cells harbored a smaller BrdU-positive population in response to DNA damage by etoposide, but remained constant at high levels in RCC4 cells (Figure 6d ). On the basis of these results, we conclude that pVHL deficiency initiates deregulated Skp2 activity in response to apoptotic stimuli and impairs the regulation of the G1/S checkpoint that is guided by p27/kip1 induction.
Discussion
Our study shows that pVHL enhances p27/kip1 induction by destabilizing Skp2. Moreover, DNA damageinduced Skp2 destabilization promotes p27/kip1 stabilization to affect S-phase arrest by inhibiting the synthesis of mutated DNA; this selective regulation of the Skp2-p27/kip1 axis is regulated by the status of VHL. On the basis of its findings, this study identifies a novel function of pVHL, to suppress tumor progression.
Low levels of p27/kip1 correlate with high tumor grades or poor survival (Sgambato et al., 2000; Nho and Sheaff, 2003) ; thus, p27/kip1 has been proposed to be a tumor suppressor, as evidenced by its negative regulation of progression through the G1/S phase. As a result, identifying the regulatory mechanism of p27/kip1 is critical for elucidating the process of tumor cell proliferation. In human cancers, p27/kip1 regulates through Skp2-mediated ubiquitination and proteasomal degradation (Bloom and Pagano, 2003) . Moreover, a stable interaction between Skp2 and p27/kip1 depends on cyclin-dependent kinase2/cyclin E-mediated phosphorylation at Thr-187. HA-Skp2, HA-Skp2 S72A and HA-Skp2 S72D phosphomimetic mutant were transiently transfected with HA-pVHL into HEK293T cells. Bound pVHL was analyzed by immunoprecipitation with anti-HA. For (d), the phospho-defective HA-Skp2 S72A and phospho-mimetic mutant HA-Skp2 S72D was compared with wildtype HA-Skp2 for degradation by HA-pVHL, as determined by immunoblot. Relative density after HA-pVHL expression was measured by densitometry, as indicated under the blot. (e) DNA damage-induced inhibition of Skp2 phosphorylation. Indicated proteins were overexpressed in HEK293T cells for 24 h and treated with adriamycin (0.4 mg/ml) or etoposide (10 mM) for 8 h. To detect phospho-Skp2, total cell lysates were immunoprecipitated and immunoblotted.
In contrast to p27/kip1 repression, which has been reported in various cancers, amplification and overexpression of Skp2 is a significant event in human cancer. Unlike p27/kip1, which is referred to as a tumor suppressor, Skp2 is an oncogene and a strong prognostic marker of cancer development. Thus, the identification of the molecular mechanism that underlies the inverse expression of p27/kip1 and Skp2 might suggest a tumorigenesis model and furnish novel therapeutic strategies.
During cell proliferation, p27/kip1 levels oscillate precisely, peaking during G0 (quiescence) and G1, but p27/kip1 mRNA is constant. As discussed earlier, the level of p27/kip1 is entirely regulated by Skp2-mediated ubiquitination.
Whether DNA-damage-induced cell cycle arrest at G0/G1 requires activated p27/kip1 is undetermined. Some reports suggest that the induction of p27/kip1 by DNA damage is unaltered (Vikhanskaya et al., 1996; Balasubramanian et al., 1999; Vivo et al., 2003) , but others have observed increases in p27/kip1 increment (Zhou et al., 2004; He et al., 2006; Cuadrado et al., 2009) .
We found that pVHL stabilizes p27/kip1, which relies on inhibited ubiquitination and degradation by Skp2. Inhibition of pVHL expression with an shRNA-encoding lentivirus decrease p27/kip1 levels, and etoposideinduced p27/kip1 accumulation was also impaired. This result raises the possibility that pVHL regulates the ubiquitin ligase activity of Skp2. We found that pVHL associated with Skp2 through its b-domain, to which HIFa binds. The interaction between pVHL and Skp2 reinforced the latter's ubiquitination and degradation, but has no impact on the E3 ubiquitin ligase activity of pVHL. Notably, the DNA damage-induced Skp2 destabilization that coincided with the accumulation of p27/kip1 requires pVHL, because the DNA damageinduced ubiquitination and degradation were defective in pVHL-silenced cells.
On the basis of a recent study, in which Akt-mediated phosphorylation was shown to be required for Skp2 stability and activity, we concluded that pVHL interfered with Akt1 and Skp2 interaction, and then allowed the dephosphorylated forms of Skp2 for rapid degradation.
Using VHL-deleted RCC4-null cells and pVHLrecovered stable cells, we observed that the restoration of VHL resulted in the abnormal accumulation of endogenous Skp2 protein and uncontrolled DNA synthesis during the S phase. On the basis of these data, we propose that pVHL regulates the Skp2-p27/kip1 axis in response to apoptotic stimuli to control cellular growth.
Recently, several roles of Skp2 in generating malignant tumors were suggested (Kitagawa et al., 2008) in a report that observed that Skp2 suppressed p53 stabiliza- tion and p53-mediated apoptosis on DNA damage. This result was due to the inhibition of p300-mediated acetylation of p53 through interference of the p53-p300 interaction by Skp2. Under normal conditions, Skp2 binds to p300 and inhibits acetylation of p53, but Skp2 loses its affinity for p300 on DNA damage; consequently, p53 can be acetylated by p300. Notably, we previously found that pVHL regulates p53 with regard to stabilization and transactivation by enhancing p300-mediated acetylation (Roe et al., 2006) . This independent molecular regulation during DNA damage, including pVHL-mediated activation of p53, liberation from suppression of p53-p300 signaling by Skp2 and our results in this report are intertwined. We speculate that pVHL-mediated destabilization of Skp2 synergizes with p53 transactivation, enabling two effective tumor suppressors-p21/Cip1 and p27/ Kip1-to arrest the cell cycle and inhibit growth (Figure 7) .
We identified a molecular network through which pVHL provides tumor suppressor function by inactivating Skp2 and activating p27/kip1 after DNA damage. When the amplification of Skp2 and reduction of p27/ kip1 occur simultaneously in renal tissues, malignant tumors develop and patients experience shorter diseasefree survivals. Thus, our study provides a rationale for targeting pVHL-dependent Skp2 regulation in the development and treatment of renal cancer.
Materials and methods
Cells
HEK293T and HCT116 cells were obtained from ATCC. pVHL-null RCC4 cells were obtained from Dr B Bruene (Johann Wolfgang Goethe-University, Frankfurt am Main, Germany). RCC4 and RCC4/pVHL stable cells were selected using G418 (1 mg/ml) from RCC4 cells that were transiently transfected with pCDNA3.0 and pCR3-HA-VHL plasmid. Stable colonies were picked and maintained in G418 (800 mg/ ml). Except for the RCC4 cells, the cells were cultured in Dulbecco's modified Eagle's medium, containing 5% (v/v) fetal bovine serum, 5% (v/v) calf serum, and 50 U/ml penicillin and streptomycin. The media for RCC4 cells were supplemented with 10% (v/v) fetal bovine serum and 1.0 mg/l ciprofloxacin (Sigma, St Louis, MO, USA).
DNA and transfection
Mammalian expression vectors for pCDNA3-Flag-Skp2 were obtained from Dr DS Lim (KAIST, Daejeon, South Korea). The expression vectors for full-length Skp2 were generated by inserting Skp2 PCR fragments into pCDNA3-HA. Mammalian expression vectors for full-length or truncated pVHL mutants were generated as described. The point mutant was developed using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Detailed information about the DNA that was used in this study is available on request. DNA transfection was performed using Lipofectamine according to the manufacturer's instructions (Invitrogen, Carlsland, CA, USA).
Purification of recombinant proteins
Recombinant GST-fused full-length or deletion mutants of pVHL were obtained as described previously (Roe et al., 2006) .
Immunoprecipitation and immunoblotting
Cells were lysed with lysis buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% (v/v) NP-40, 1 Â protease inhibitor cocktail (Roche, Welwyn Garden City, UK)), and cell lysates were incubated with the appropriate antibody and protein A/ G beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoprecipitates were boiled with sodium dodecyl sulfate sample buffer, loaded onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes and probed with the suitable antibodies. The following antibodies were used in this study: anti-b-actin monoclonal antibody (mAb) and anti-Flag mAb were purchased from Sigma; anti-HA mAb was from Covance (Princeton, NJ, USA); anti-GAPDH (NB300-221D) mAb from Novus Biological; anti-Skp2 (H-435) pAb, anti-immunoglobulin G mAb and anti-ubiquitin (P401) were from Santa Cruz Biotechnology; anti-Skp2 (32-3300) mAb from Invitrogen; anti-phospho (Ser/Thr) Akt substrate pAb substrate was from Cell Signaling; and anti-pVHL (Ig33) mAb was from BD PharMingen (San Diego, CA, USA). Rabbit polyclonal antipVHL antibody was generated as described (Hergovich et al., 2003) .
Immunofluorescent staining
To detect the S-phase distribution after an 8-h etoposide treatment, RCC4 and RCC4/pVHL stable cells were fixed with 4% (w/v) paraformaldehyde, permeabilized with 0.5% Triton X-100 and blocked with 2% (w/v) bovine serum albumin in phosphate-buffered saline. The cells were stained with fluorescein isothiocyanate-conjugated BrdU mAb. Immunofluorescence was measured on a Zeiss LSM 510 laser scanning microscope. After three independent experiments, the relative fluorescent strength of BrdU versus 4 0 ,6-diamidino-2-phenylindole was calculated using the LSM image browser program (Carl Zeiss, Jena, Germany).
In vivo ubiquitination assay HEK293T or HCT116 cells were transfected with different combinations of plasmids. Transfected cells were treated with 10 mM MG132 (Calbiochem, San Diego, CA, USA) for 16 h and lysed with lysis buffer. Supernatants were immunopreci- pitated with the proper antibody, and washed immunoprecipitates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed with anti-ubiquitin.
RNA purification and qRT-PCR Total RNA from cells was prepared using TRI Reagents (Molecular Research Center, Cincinnati, OH, USA). For synthesis of cDNA, total RNA was reverse-transcribed with reverse transcriptase (AMV-XL reverse transcriptase, Takara) using random hexamer (Takara, Ohtsu, Japan). qRT-PCR was performed as described in the manufacturer's instruction (DyNAmo HS SYBR Green qPCR Kit, Finnzymes, Espoo, Finland). The accumulations of specific products in a reaction were continuously monitored by iCycler Real-Time PCR (Bio-Rad).
RNA interference
For viral-mediated RNA interference of VHL, lentiviral vector that contained VHL-targeting sequences (pLKO.1-shVHL (RHS3979-9607016)) was used. Lentiviral backbone plasmid was co-transfected with vector helper plasmids pLP1, pLP2 and pLP/VSV-G into 293FT packaging cells. As a control, pLKO.1 scrambled was used for lentiviral backbone plasmid. These lentiviral vectors were purchased from Open Biosystems (Huntsville, AL, USA) and helper plasmids were purchased from Invitrogen.
Densitometry analysis
Densitometry was determined with the NIH ImageJ v.1.42q software with normalization to the corresponding controls (b-actin and input).
Statistical analysis
All assays were repeated at least three times. These results of quantitative studied are reported as mean±s.d. Differences were analyzed by Student's t-test. Po0.05 was regarded as significant.
